Prodrugs of Chlorokynurenines

A compound having the structure of formula (I), (II), (III), (IV), (V), (VI), (VII), or (VIII), or a pharmaceutically acceptable salt, stable isotope, or stereoisomer thereof:

• wherein:
• R1 and R2 are, independently, optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclyl;
• or
• R1 and R2, together with the atoms to which they are attached, form an optionally substituted 4- to 8-membered heterocycle;
• R3 is H, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkoxy, optionally substituted arylC1-6 alkyleneoxyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, —NH2, —NHC1-6 alkyl, —N(C1-6 alkyl)2, optionally substituted heteroaryl, or optionally substituted heterocyclyl;
• R4 is H, optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclyl;
• R4′ is optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclyl;
• R5 is optionally substituted C1-10 alkyl, optionally substituted aryl, optionally substituted alkylene glycol, —P(O)(OH)2, —P(O)(OH)(OC1-6alkyl), or —S(O)2OH;
• R6 is H, an amino acid moiety, or a peptide moiety;
• R7 is OH, an amino acid moiety, or a peptide moiety;
• wherein at least one of R6 and R7 is an amino acid moiety or a peptide moiety comprising at least 2 amino acid moieties;
• or
• R8 is H or optionally substituted C1-6 alkyl;
• R9 is H or optionally substituted C1-6 alkyl;
• R10 and R11 are, independently, H, optionally substituted C1-6 alkyl, or SO2(C1-6 alkyl);
• or R10 and R11, together with the atoms to which they are attached, form an optionally substituted heterocyclyl;
• R12 is H, C(O)C1-6 alkyl, or C(O)OC1-6 alkyl;
• R13 is H;
• or R13 and R7 form a bond or CH2 group;
• linker is optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, or optionally substituted glycol moiety;
• and
• monomer 1 and monomer 2 are independently selected from the group consisting of a moiety of formula (I), (II), and (III);
• wherein the compound converts to 4-chlorokynurenine after administration to a human.